High Levels of Baseline HbA1c, FPG, and 2-Hour Postprandial Glucose Are Key Predictors for Not Achieving HbA1c <7.0% at Six Months in People with T2DM Starting Insulin Glargine 100 U/mL

被引：0
|
作者：
Owens, David R.
Landgraf, Wolfgang
Zhang, Mei
Frier, Brian M.
Meneghini, Luigi
Home, Philip
Bolli, Geremia B.
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1046-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] An average HbA1C of <7.0 is achievable in patients with T2DM
    Hood, RC
    DIABETES, 2002, 51 : A485 - A485
  • [2] FPG、GA、HbA1c及GA/HbA1c比值在T1DM/T2DM中的诊疗价值
    王菊英
    姚琳芳
    周立荣
    李锋
    中国免疫学杂志, 2015, 31 (11) : 1536 - 1540
  • [3] Association of hypoglycaemia with insulin titration and body weight in people with type 2 diabetes commencing insulin glargine 100 U/ml and achieving different HbA1c levels
    Frier, B. M.
    Landgraf, W.
    Zhang, M.
    Bolli, G. B.
    Owens, D. R.
    Home, P. D.
    DIABETOLOGIA, 2017, 60 : S335 - S336
  • [4] Effect of LSG on HbA1c Levels in T2DM Patients at One Year
    不详
    OBESITY SURGERY, 2009, 19 (08) : 1005 - 1006
  • [5] Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies
    Riddle, M. C.
    Vlajnic, A.
    Zhou, R.
    Rosenstock, J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (09): : 819 - 825
  • [6] Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%
    Owens, David R.
    Landgraf, Wolfgang
    Frier, Brian M.
    Zhang, Mei
    Home, Philip D.
    Meneghini, Luigi
    Bolli, Geremia B.
    DIABETES OBESITY & METABOLISM, 2019, 21 (02): : 321 - 329
  • [7] Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naive People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c
    Khan, Niaz
    Tirosh, Amir
    Vargas-Uricoechea, Hernando
    Mabunay, Maria Aileen N.
    Coudert, Mathieu
    Pilorget, Valerie
    Galstyan, Gagik R.
    DIABETES, 2021, 70
  • [8] Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI
    Kis, Janos T.
    Seufert, Jochen
    Haluzik, Martin
    Bonnemaire, Mireille
    Vera, Carine
    Tournay, Mathilde
    Freemantle, Nick
    Guja, Cristian
    DIABETES THERAPY, 2024, 15 (11) : 2337 - 2350
  • [9] Hypoglycemia as a Function of HbA1c in Type 2 Diabetes (T2DM): Insulin Glargine 300 U/mL in a Patient-Level Meta-analysis of EDITION 1, 2, and 3
    Bonadonna, Riccardo C.
    Yale, Jean-Francois
    Brulle-Wohlhueter, Claire
    Corfec, Emmanuelle Boelle-Le
    Choudhary, Pratik
    Bailey, Timothy S.
    DIABETES, 2016, 65 : A239 - A239
  • [10] Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial
    Charbonnel, Bernard
    Aroda, Vanita R.
    Westerbacka, Jukka
    Lauand, Felipe, Sr.
    Boelle, Emmanuelle
    Cheng, Alice Y.
    Rosenstock, Julio
    Bolli, Geremia B.
    DIABETES, 2019, 68
12345